ALK gene
Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival
NSCLC; biomarker testing; overall survival; PD-L1; EGFR; ALK; next-generation sequencing; liquid biopsy; precision medicine; real-world data
Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC
Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines